argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-02-19)

EUR 717.60+0.45%

argenx SE
UMushroom community rating:

4.77 3 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

16.0%1Y

108%3Y

137%5Y

Performance

34.8%1Y

39.7%3Y

38.7%5Y

Volatility

51651 M

Market cap (USD)

67,099

Daily traded volume (Shares)

600 / 594.2

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.77

3 votes

Performance:

4.54

Innovation:

5.00

Society:

4.77

Nature:

3.62

Laura Sofie Tohver

United Kingdom, 11 Nov 2025

Emerging technology and nice returns

Viktor Stockel

Switzerland, 30 Oct 2025

Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.

Claudia Stadelmann

Switzerland, 05 Mar 2025

Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

Grifols, SA

Grifols, SA Valor: 19108728

Annual Return

-50%0%+50%

Risk level

110

-2.88%USD 9.44

INTERSHOP Communications AG

INTERSHOP Communications AG Valor: 52515678

Annual Return

-50%0%+50%

Risk level

110

-3.23%EUR 1.20

artnet AG

artnet AG Valor: 13664519

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 11.30

SEVEN PRINCIPLES AG

SEVEN PRINCIPLES AG Valor: 30741641

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 5.10

NanoRepro AG

NanoRepro AG Valor: 4691951

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 1.48

beaconsmind Ltd

beaconsmind Ltd Valor: 45112358

Annual Return

-50%0%+50%

Risk level

110

0.81%EUR 4.96

Schweizer Electronic AG

Schweizer Electronic AG Valor: 1218002

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 6.50

Bio-Gate AG

Bio-Gate AG Valor: 20104373

Annual Return

-50%0%+50%

Risk level

110

-3.45%EUR 0.56

Mynaric AG

Mynaric AG Valor: 121337525

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 0.17

Playtika Holding Corp

Playtika Holding Corp Valor: 59044574

Annual Return

-50%0%+50%

Risk level

110

0.58%USD 3.46

SIX

FactSet

Clearbit

Logos provided by Clearbit